(Q34224849)

31 July 2017

1 reference

title

Taxanes in lung cancer: a review with focus on the European experience (English)

1 reference

31 July 2017

A Calderoni

1

1 reference

31 July 2017

T Cerny

series ordinal

2

1 reference

31 July 2017

publication date

1 May 2001

1 reference

Critical Reviews in Oncology Hematology

31 July 2017

published in

1 reference

31 July 2017

volume

38

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

105-127

1 reference

Microtubules and actin filaments: dynamic targets for cancer chemotherapy

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Taxol: mechanisms of action and resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Molecular effects of paclitaxel: myths and reality (a critical review).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel exposure time determines the nature of the interaction with radiation in HeLa cells. the role of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

1 reference

7 January 2021

A phase I trial of taxol given by a 6-hour intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I study of taxol using a 5-day intermittent schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Taxol administered as a 120 hour infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I trial of weekly paclitaxel in advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Induction chemotherapy before surgery for early-stage lung cancer: A novel approach

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I trial of Taxotere: five-day schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

A phase I trial of docetaxel and gemcitabine in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900121-9

7 January 2021

10.1016/S1040-8428(00)00121-9

Identifiers

DOI

1 reference

31 July 2017

1 reference